(Pfizer) Pfizer announced that it is expecting $36 billion in vaccine sales revenue by the close of the year and $29 billion next year with the increasing vaccine shipment.
Pfizer’s diluted EPS increased 129% to $1.34 in the third quarter of 2021, from $0.59 reported in the same quarter of last year.
The company generated $13 billion in vaccine revenue in the third quarter against analysts’ projected revenue of $11 billion.
Pfizer has upgraded the FY21 revenue to be between $81 billion and $82 billion. Previous projections were between $78 and $80 billion.
The company also projects earnings per share of between $4.13 and $4.18, an increase from the previous estimates of between $3.95 and $4.05 EPS.
PFE: NYSE is up +4.38%
